Tobira is currently running CENTAUR, a global randomized Phase 2 study of CVC vs placebo in patients with NASH and liver fibrosis. For more information about the CENTAUR study, visit www.clinicaltrials.gov, trial identifier NCT02217475.
http://www.tobiratx.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Friday
LOAD TIME
0.7 seconds
PAGES IN
THIS WEBSITE
15
SSL
EXTERNAL LINKS
113
SITE IP
69.63.141.107
LOAD TIME
0.656 sec
SCORE
6.2
Tobira Therapeutics | CVC for NASH | CENTAUR study | tobiratx.com Reviews
https://tobiratx.com
Tobira is currently running CENTAUR, a global randomized Phase 2 study of CVC vs placebo in patients with NASH and liver fibrosis. For more information about the CENTAUR study, visit www.clinicaltrials.gov, trial identifier NCT02217475.
Investor Relations - Tobira Therapeutics
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies targeting serious diseases of immune-inflammation and fibrosis. The company’s lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5. CVC is being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and has received FastTrack Designation from the FDA. Oct 20, 2016. Oct 19, 2016. Sep 21, 2016 at 2:30 PM PT.
tobiratx.com
CVC for NASH | CENTAUR study | Tobira Therapeutics Inc.
http://www.tobiratx.com/patient-resources/nash
The rising prevalence of obesity-related disorders has contributed to a rapid rise in the prevalence of NASH. In the United States, NASH affects an estimated 9 million to 15 million people, or 3 to 5 percent of the population, with similar prevalence in the EU and China. Driven by the obesity epidemic, NASH is projected to become the leading cause of liver transplants by the year 2020. Currently no therapies are approved for the treatment of NASH. Presence of obesity, especially morbid obesity (BMI 35).
Values | Tobira Therapeutics Inc.
http://www.tobiratx.com/careers/values
To bring unique therapies to patients efficiently, with urgency and pupose. Tobira’s Core Values. Eamwork – Proactively demonstrates responsibility, communication and problem solving with other team members to ensure achievement of all company goals; helps others succeed. Bjective Driven – Tenacious in striving to reach goals and consistently pushes self and others to achieve results; gets things done. Old - Willing to take calculated risk to make a meaningful difference for patients. Hane Chow, Inc.
Clinical Trials | Tobira Therapeutics Inc.
http://www.tobiratx.com/pipeline/clinical-trials
Clinical trials are biomedical or health-related research studies in human beings that follow a pre-defined protocol. A clinical trial is conducted to answer questions about a certain disease, to test new treatments, or to investigate new ways of using known treatments. Why participate in a clinical trial? Who can participate in a clinical trial? Tobira is sponsoring the following Clinical trials…. Ndash; Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects with Primary Sclerosing Cholangitis.
Partnering | Tobira Therapeutics Inc.
http://www.tobiratx.com/about/partnering
Tobira is seeking in-licensing and combination therapy development partners for our therapies in fibrosis, inflammation and HIV. Please direct Corporate Development inquiries to:. In April 2016, Tobira entered into license agreements with Dong-A ST. Ltd. Tobira acquired the exclusive rights to develop and market evogliptin in the United States, Canada, Europe and Australia. Dong-A received an exclusive license to develop and market CVC in the Republic of Korea. 701 Gateway Blvd, Suite 300. Hane Chow, Inc.
Cenicriviroc (CVC) | CENTAUR study | NASH study | Tobira study | Tobira Therapeutics Inc.
http://www.tobiratx.com/about
We are a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat non-alcoholic steatohepatitis (NASH) and other liver diseases, inflammation, fibrosis and HIV. Our lead product candidate, cenicriviroc, or CVC, is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of NASH, primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV. If approved, the company intends to establi...
TOTAL PAGES IN THIS WEBSITE
15
Board of Directors - Tobira Therapeutics
http://ir.tobiratherapeutics.com/directors.cfm
Chairman of the Board. Member of the Nominating and Governance Committee. Carol L. Brosgart, M.D. Carol L. Brosgart, M.D. Member of the Nominating and Governance Committee. Jeffrey H. Cooper. Member of the Audit Committee. Chair of the Nominating and Governance Committee. Laurent Fischer, M.D. Laurent Fischer, M.D.,. Andrew J. Fromkin. Member of the Audit Committee. Chair of the Compensation Committee. Member of the Compensation Committee. Chair of the Audit Committee. Member of the Compensation Committee.
SEC Filings - Tobira Therapeutics
http://ir.tobiratx.com/sec.cfm
All Filings (excluding Section 16). Feb 14, 2017. Amended statement of beneficial ownership. File is in Briefcase. Jan 18, 2017. Amended statement of beneficial ownership. File is in Briefcase. Nov 14, 2016. Certification of termination of registration. File is in Briefcase. Nov 4, 2016. Amended general statement of beneficial ownership. File is in Briefcase. Nov 4, 2016. File is in Briefcase. Nov 3, 2016. File is in Briefcase. Nov 3, 2016. File is in Briefcase. Nov 3, 2016. File is in Briefcase.
Events & Presentations - Tobira Therapeutics
http://ir.tobiratx.com/events.cfm
Details on upcoming events are not yet available. Please click here. To be notified of all upcoming events. Sep 13, 2016. Tobira Investor Presentation - September. File is in Briefcase. Sep 21, 2016. Aegis Capital Corp. 2016 Growth Conference. Sep 13, 2016. Rodman and Renshaw 18th Annual Global Investment Conference. Aug 10, 2016. 36th Annual Canaccord Genuity Growth Conference. Aug 9, 2016. Tobira 2016 Second Quarter Financial Results Conference Call. File is in Briefcase. Jul 25, 2016. Jun 21, 2016.
Stock Information - Tobira Therapeutics
http://ir.tobiratx.com/stockquote.cfm
4:00 PM ET on Oct 31, 2016. The stock information provided is for informational purposes only and is not intended for trading purposes. The stock information is provided by eSignal, stock charts are provided by EDGAR Online, both third party services, and Tobira Therapeutics does not maintain or provide information directly to this service. Stock information is delayed approximately 20 minutes. Sign up for email alerts. 4:00 PM ET on Oct 31, 2016. Delayed at least 20 minutes. 701 Gateway Blvd, Suite 300.
Investor FAQs - Tobira Therapeutics
http://ir.tobiratx.com/faq.cfm
On what stock exchange are Tobira Therapeutics shares traded, and what is the ticker symbol? The Tobira Therapeutics is traded on the NASDAQ under the symbol “TBRA”. When was Tobira Therapeutics' Initial Public Offering? Tobira Therapeutics became a public company effective May 04, 2015 resulting from a reverse merger with Regado Biosciences. Regado Biosciences became a publicly traded company on August 22, 2013 through an initial public offering (IPO). 701 Gateway Blvd, Suite 300. Ernst and Young LLP.
- Tobira Therapeutics
http://ir.tobiratherapeutics.com/eventdetail.cfm?EventID=161370
Details on this event are not available. 4:00 PM ET on Oct 31, 2016. Delayed at least 20 minutes. 701 Gateway Blvd, Suite 300. South San Francisco, CA 94080. 2016 Tobira Therapeutics, Inc. Hane Chow, Inc.
Analyst Coverage - Tobira Therapeutics
http://ir.tobiratherapeutics.com/analysts.cfm
Tobira Therapeutics is covered by the following analysts. Elemer Piros, PhD. Please note that any opinions, estimates or forecasts regarding Tobira Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Tobira Therapeutics or its management. Tobira Therapeutics does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. 4:00 PM ET on Oct 31, 2016.
Annual Reports and Proxies - Tobira Therapeutics
http://ir.tobiratherapeutics.com/annuals-proxies.cfm
Annual Reports and Proxies. File is in Briefcase. Mar 3, 2016. File is in Briefcase. Feb 12, 2015. File is in Briefcase. Mar 12, 2014. File is in Briefcase. Apr 28, 2016. File is in Briefcase. Jun 4, 2015. File is in Briefcase. May 5, 2014. File is in Briefcase. Add file to Briefcase. 4:00 PM ET on Oct 31, 2016. Delayed at least 20 minutes. 701 Gateway Blvd, Suite 300. South San Francisco, CA 94080. 2016 Tobira Therapeutics, Inc. Hane Chow, Inc.
Press Releases - Tobira Therapeutics
http://ir.tobiratx.com/releases.cfm
Oct 20, 2016. Tobira Therapeutics Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting. Cenicriviroc Significantly Improved Fibrosis without Worsening of NASH at One Year SOUTH SAN FRANCISCO, Calif.- (BUSINESS WIRE)- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholi. File is in Briefcase. Oct 19, 2016. File is...
Board of Directors - Tobira Therapeutics
http://ir.tobiratx.com/directors.cfm
Chairman of the Board. Member of the Nominating and Governance Committee. Carol L. Brosgart, M.D. Carol L. Brosgart, M.D. Member of the Nominating and Governance Committee. Jeffrey H. Cooper. Member of the Audit Committee. Chair of the Nominating and Governance Committee. Laurent Fischer, M.D. Laurent Fischer, M.D.,. Andrew J. Fromkin. Member of the Audit Committee. Chair of the Compensation Committee. Member of the Compensation Committee. Chair of the Audit Committee. Member of the Compensation Committee.
TOTAL LINKS TO THIS WEBSITE
113
とびら of 東京バイオマーカー・イノベーション技術研究組合
とびら of 東京バイオマーカー イノベーション技術研究組合. Ssociation:TOBIRA は産 官 学 医が密接に連携し、有用なバイオ-マーカーを用いて、超早期発見や治療効果予測など次世代の診断やその測定機器の開発、ならびに、これらを迅速に評価ができる臨床研究の整備に取り組み、がん、生活習慣病、感染症、虚血性疾患など多くの疾患の 早診完治 による先進医療都市 東京 の実現を目指しています。 この度、東京バイオマーカーイノベーション技術研究組合 TOBIRA は、オープンイノベーションにより新医療技術および新医療機器の早期実用化を支援する トビラ バイオテクノロジー パートナーズ TOBIRA BioTechnology Partners を設置しました。 TOBIRA BioTechnology Partners seminar.
Tobira Records
Tobira Records new web site is open. Thank you for assistance. Tobira Compilation vol.1 out now. Tobira Compilation vol.1. Available:June 30th, 2011. 01 greg davis "mindmirror". 02 nobuto suda "ephemeral". 03 sean mccann "guardian". 04 ieva "invisible live at cafe indepandant". 05 hakobune "isolated resonance of". 06 celer "remaining open to grace". 07 celer "the thing that makes everything else unimportant". 08 david tagg "guitar and water". 09 brian grainger "bottleneck". 10 richard lainhart "forming".
Tobira Records
Hakobune “A Distant Loss”. Garden Of Ghosts “Garden Of Ghosts”. Hakobune “Recalling My Insubstantial Thoughts”. Saturn Form Essence “Philosophy Of Chaos Structure”. Hakobune “Trace”. Various “Tobira Compilation Vol.1″. Hakobune “Sense Of Place”. Hakobune “Momentarily Endless”. Nobuto Suda “Sensitive Fields”. Garden Of Ghosts “風土”. Somukenai / Learned Helplesness “Split”. Nobuto Suda “Bloom”. Hiroki Sasajima “Crossion”. Richard Lainhart / Hakobune “Untitled”.
Tobira Therapeutics | CVC for NASH | CENTAUR study
Targeting serious diseases of. Our lead product candidate cenicriviroc (CVC) is under evaluation to treat non-alcoholic steatohepatitis (NASH) with liver fibrosis and other serious illnesses. NASH is a severe type of non-alcoholic fatty liver disease, or NAFLD. NASH affects 3 to 5 percent of the US population and can lead to life-threatening complications such as cirrhosis and liver cancer. There are no approved therapies for patients suffering from this severe condition. CVC Development in NASH.
Tobira Therapeutics | CVC for NASH | CENTAUR study
Non-Alcholic Steatohepatitis – A Global Epidemic. Cenicriviroc (CVC) – a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5. Building a leading platform of anti-inflammatory and anti-fibrotic therapies for serious liver disease. We are focused on the development and commercialization of therapies to change the course of the NASH epidemic and other serious liver diseases. Developing Novel Treatments for Chronic Liver Disease. October 20, 2016. October 19, 2016. October 3, 2016.
TobiRawrr (Tobi) - DeviantArt
Window.devicePixelRatio*screen.width 'x' window.devicePixelRatio*screen.height) :(screen.width 'x' screen.height) ; this.removeAttribute('onclick')" class="mi". Window.devicePixelRatio*screen.width 'x' window.devicePixelRatio*screen.height) :(screen.width 'x' screen.height) ; this.removeAttribute('onclick')". Join DeviantArt for FREE. Forgot Password or Username? Deviant for 8 Years. This deviant's full pageview. Last Visit: 331 weeks ago. This is the place where you can personalize your profile! Favouri...
門扉の事なら片倉建鉄へ 門扉 フェンス 電動門扉 手作り門扉 高級門扉 メーカー
門扉 両開き 引き戸 大型門扉 電動門扉 monnpi. カラクラのTOPページ 堅実な門扉の設計施工 デザイン門扉 の総合メーカー 手作り門扉はカタクラで. 1966年 昭和41 6月25日 創業49年. 本 社 神奈川県横浜市神奈川区片倉5丁目2番5号 経理業務. 工 場 神奈川県横浜市神奈川区羽沢町47-4 営業 設計 製作 工事. お問い合わせ番号 ０４５ ３８１ ５５６６ ＦＡＸ０４５ ３８１ ５５６８. 更新日 ( ο )ゝ.
[豆本の扉や]TOP
H t t p : / / t o b i r a y a . n e t /. 店主西イズミが文 絵 製本などの過程をプリンタやPCの力を借りつつ、一冊一冊 手作業で本の形にこさえています。 掲載情報、イベント情報など更新するブログ http:/ tobiraya.net/blog/. 2011年に発売された猫と猫と暮らす人のための本 第２弾の 新装版 が発売されました.
劇団扉座公式サイト～厚木市・市民が一体となったプロジェクトのほか、ワークショップなど様々な活動を展開しています～
また、厚木にて市民 応援団 厚木市文化会館と3者で 厚木シアタープロジェクト を結成。 つか版 忠臣蔵 大願成就討ち入り篇 (2014年). つか版 忠臣蔵 スカイツリー篇 Returns (2013年). 人情噺 端敵 天下茶屋 (2012年). つか版 忠臣蔵 スカイツリー篇 東京 厚木あゆコロ篇 厚木 2012年. LOVE LOVE LOVE 15. LOVE LOVE LOVE R36. 第36回岸田國士戯曲賞 作品名 愚者には見えないラマンチャの王様の裸 を受賞. 第28回大谷賞 作品名 新 三国志 を史上最年少で受賞. ドアクラブ優先予約 扉座へ電話予約のみ 9月12日 土 12:00 18:00. 平日12:00 18:00 平日12:00 18:00 前売開始日以外の土 日 祝休 公演中12:00 16:00 11月5日休. また、厚木にて市民 応援団 厚木市文化会館と3者で 厚木シアタープロジェクト を結成。
